Kipspharma Appoints Park Hongjin as New Vice President of Pharmaceuticals to Lead R&D ... "Strengthening Research and Development Capabilities"

Kips Biopharma (hereafter Kipspharma) announced on July 21 that it has appointed Park Hongjin, former Vice President of Aliko Pharmaceutical, as its new Vice President to strengthen its research and development (R&D) capabilities.

Vice President Park graduated from the College of Pharmacy at Sungkyunkwan University and earned a master's degree in clinical pharmacy from the same graduate school. He joined Korea Otsuka Pharmaceutical, where he was responsible for Good Manufacturing Practice (GMP) as the head of manufacturing management, later serving as plant manager and Executive Director of Clinical Development. He is a veteran in the R&D field, having managed development and business operations at companies such as Korea Santen Pharmaceutical and VivaZon Pharmaceutical.

Notably, during his tenure at Aliko Pharmaceutical, Vice President Park personally and successfully conducted bioequivalence studies for more than 20 generic drugs.

Kipspharma currently manufactures, distributes, and sells about 180 generic drug products, many of which are subject to price reassessment. The company plans to defend against price reductions and improve profit margins by directly conducting bioequivalence studies. With Vice President Park joining, Kipspharma's strategy to enhance profit margins through bioequivalence studies is expected to gain further momentum.

Vice President Park stated, "I will faithfully implement mid- to long-term R&D plans in line with the company's rapidly growing sales targets as we expand our product portfolio and sales network. I will do my utmost to strengthen Kipspharma's fundamentals and drive external growth by leveraging the diverse expertise I have accumulated in the pharmaceutical industry."

Kim Hayong, CEO of Kipspharma, said, "Vice President Park is an expert with experience in all areas of pharmaceutical development, production, and commercialization, including new product registration (RA), pharmacovigilance (PV), and FDA GMP approval. We expect that he will make a significant contribution to the development of the oral peptide drug delivery platform, which is the main pipeline of our subsidiary, Kips Biomed."

This content was produced with the assistance of AI translation services.